Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pyxis Oncology, Inc.

1.17
+0.03002.63%
Post-market: 1.170.00000.00%16:04 EDT
Volume:350.76K
Turnover:408.74K
Market Cap:72.48M
PE:-0.75
High:1.19
Open:1.16
Low:1.14
Close:1.14
Loading ...

Pyxis Oncology Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Mar

U.S. RESEARCH ROUNDUP-AT&T, Brighthouse Financial, ETSY

Reuters
·
19 Mar

Pyxis Oncology Advances Cancer Therapeutics with MICVO

TIPRANKS
·
19 Mar

Pyxis Oncology Inc : Jefferies Cuts Target Price to $6 From $12

THOMSON REUTERS
·
19 Mar

Pyxis Oncology (PYXS) Gets a Hold from William Blair

TIPRANKS
·
19 Mar

Pyxis Oncology FY Net Income USD -77.331 Million

Reuters
·
18 Mar

Pyxis Oncology FY Basic EPS USD -1.32

THOMSON REUTERS
·
18 Mar

Press Release: Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dow Jones
·
18 Mar

Pyxis Oncology Inc expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
17 Mar

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

GlobeNewswire
·
03 Mar

Pyxis Oncology granted Fast Track designation for PYX-201 monotherapy

TIPRANKS
·
26 Feb

Pyxis Oncology Granted FDA Fast Track Designation for Pyx-201 Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer

THOMSON REUTERS
·
26 Feb

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

GlobeNewswire
·
26 Feb

Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?

Simply Wall St.
·
23 Feb

Pyxis Oncology initiates new PYX-201 trial, initiates cohort expansions

TIPRANKS
·
04 Feb

Pyxis Oncology Initiates New Pyx-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

THOMSON REUTERS
·
04 Feb